Aethon Therapeutics treats cancer by combining immunotherapy and targeted treatment to increase its effectiveness.
Aethon Therapeutics has raised $30.0M in total funding. The most recent round was Series A. The last funding was announced in January 2023.
Aethon Therapeutics's investors include Apple Tree Partners, NYU Langone Health.
Aethon Therapeutics is headquartered in New York, United States.
Aethon Therapeutics treats cancer by combining immunotherapy and targeted treatment to increase its effectiveness.
Aethon Therapeutics is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Aethon Therapeutics — Funding & Investors." VCBacked, January 9, 2023, https://www.vcbacked.co/company/aethon-therapeutics. Accessed November 13, 2026.
VCBacked. (2023). Aethon Therapeutics — Funding & Investors. Retrieved November 13, 2026, from https://www.vcbacked.co/company/aethon-therapeutics
{{cite web |title=Aethon Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/aethon-therapeutics |website=VCBacked |access-date=November 13, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated
Work at Aethon Therapeutics? Request a listing update